The stock of Enfusion Inc (ENFN) has seen a -2.73% decrease in the past week, with a -3.14% drop in the past month, and a 13.90% flourish in the past quarter. The volatility ratio for the week is 3.97%, and the volatility levels for the past 30 days are at 2.80% for ENFN. The simple moving average for the last 20 days is -1.80% for ENFN’s stock, with a simple moving average of 1.75% for the last 200 days.
Is It Worth Investing in Enfusion Inc (NYSE: ENFN) Right Now?
Enfusion Inc (NYSE: ENFN) has a price-to-earnings ratio of 191.32x that is above its average ratio. Additionally, the 36-month beta value for ENFN is 0.98. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ENFN is 47.12M and currently, short sellers hold a 4.61% ratio of that float. The average trading volume of ENFN on May 10, 2024 was 416.94K shares.
ENFN) stock’s latest price update
The stock price of Enfusion Inc (NYSE: ENFN) has dropped by -5.22 compared to previous close of 9.77. Despite this, the company has seen a fall of -2.73% in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-09 that While the top- and bottom-line numbers for Enfusion (ENFN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Analysts’ Opinion of ENFN
Many brokerage firms have already submitted their reports for ENFN stocks, with Goldman repeating the rating for ENFN by listing it as a “Sell.” The predicted price for ENFN in the upcoming period, according to Goldman is $8 based on the research report published on February 28, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see ENFN reach a price target of $9, previously predicting the price at $11. The rating they have provided for ENFN stocks is “Underweight” according to the report published on January 30th, 2024.
UBS gave a rating of “Neutral” to ENFN, setting the target price at $9 in the report published on November 07th of the previous year.
ENFN Trading at 0.64% from the 50-Day Moving Average
After a stumble in the market that brought ENFN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.92% of loss for the given period.
Volatility was left at 2.80%, however, over the last 30 days, the volatility rate increased by 3.97%, as shares sank -2.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.07% upper at present.
During the last 5 trading sessions, ENFN fell by -2.73%, which changed the moving average for the period of 200-days by -14.97% in comparison to the 20-day moving average, which settled at $9.42. In addition, Enfusion Inc saw -4.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENFN starting from Campobasso Matthew, who sale 108 shares at the price of $8.73 back on Feb 29 ’24. After this action, Campobasso Matthew now owns 30,840 shares of Enfusion Inc, valued at $943 using the latest closing price.
Gutowski Valeria, the Chief Accounting Officer of Enfusion Inc, sale 27 shares at $8.73 during a trade that took place back on Feb 29 ’24, which means that Gutowski Valeria is holding 17,570 shares at $236 based on the most recent closing price.
Stock Fundamentals for ENFN
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.67 for the gross margin
The net margin for Enfusion Inc stands at 0.04. The total capital return value is set at 0.13. Equity return is now at value 10.18, with 5.19 for asset returns.
Based on Enfusion Inc (ENFN), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at 1.59. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is 8.93.
Currently, EBITDA for the company is 20.54 million with net debt to EBITDA at -0.98. When we switch over and look at the enterprise to sales, we see a ratio of 4.71. The receivables turnover for the company is 6.22for trailing twelve months and the total asset turnover is 1.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.44.
Conclusion
In conclusion, Enfusion Inc (ENFN) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
